Table 6. Sensitivity analysis; assuming treatment dependent DM health state costs - probabilistic.
Trastuzumab | No trastuzumab | Increment | ICER | ||||
---|---|---|---|---|---|---|---|
Costs | QALYs | Costs | QALYs | Costs | QALYs | ||
Real world scenario | € 176,541 | 13.927 | € 315,715 | 13.097 | -€ 139,175 | 0.830 | Dominance |
Guideline scenario | € 165,256 | 13.551 | € 293,593 | 12.686 | -€ 128,337 | 0.865 | Dominance |
Trial scenario | € 181,133 | 14.095 | € 357,625 | 13.103 | -€ 176,492 | 0.993 | Dominance |